Video: Latest Treatment for Hep C.

Salitop Lotion

Generic Name: salicylic acid
Dosage Form: lotion

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Salitop™ Cream (6% Salicylic Acid)
Salitop™ Lotion (6% Salicylic Acid)

Rx Only

FOR DERMATOLOGICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.

Salitop Lotion Description

Salitop™ Cream contains 6% w/w Salicylic Acid USP finely dispersed in an emulsion consisting of Ammonium Lactate, Behentrimonium Chloride, Cetyl Alcohol, Dimethicone 360, Disodium EDTA, Glycerin, Glyceryl Stearate SE, Methylparaben, Mineral Oil, PEG-100 Stearate, Phenoxyethanol, Propylparaben, Purified Water and Trolamine.

Slideshow: Foodborne Illness: The Thanksgiving Guest Nobody Invited

Salitop™ Lotion contains 6% w/w Salicylic Acid USP finely dispersed in an emulsion consisting of Ammonium Lactate, Behentrimonium Chloride, Cetyl Alcohol, Dimethicone 360, Disodium EDTA, Glycerin, Glyceryl Stearate SE, Methylparaben, Mineral Oil, PEG-100 Stearate, Propylparaben, Purified Water, Trolamine.

Salicylic acid is the 2-hydroxy derivative of benzoic acid having the following structure:

This formulation is designed to provide sustained release of the active ingredient into the skin.

Salitop Lotion - Clinical Pharmacology

Salicylic acid has been shown to produce desquamation of the horny layer of skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acid in a 6% salicylic acid gel in four patients with extensive active psoriasis, Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 mL even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100 mL). Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to dehydration or diuretics have higher salicylate levels than those with a normal extracellular space (see PRECAUTIONS).

The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space.

Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs; by similar competitive mechanisms other drugs can influence the serum levels of salicylate (see PRECAUTIONS).

Indications and Usage for Salitop Lotion

For Dermatologic Use

Salitop™ is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris and psoriasis (including body, scalp, palms and soles).

For Podiatric Use

Salitop™ is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares.

Contraindications

Salitop™ should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. Salitop™ should not be used on children under 12 years of age.

Warnings

Prolonged and repeated daily use over large areas, especially in children and those patients with significant renal or hepatic impairment, could result in salicylism. Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid. Excessive application of the product other than is needed to cover the affected area will not result in a more rapid therapeutic benefit. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal or hepatic impairment, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances. In the event of salicylic acid toxicity, the use of Salitop™ should be discontinued. Fluids should be administered to promote urinary excretion. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal anti-inflammatory agent that is not salicylate based.

Due to the potential risk of developing Reye's Syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by a physician.

Precautions

For external use only. Avoid contact with eyes and other mucous membranes.

Pregnancy (Category C)

Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. Salitop™ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Because of the potential for serious adverse reactions in nursing infants from the mother's use of Salitop™, a decision should be make whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If used by nursing mothers, it should not be on the chest area to avoid the accidental contamination of the child.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No data are available concerning potential carcinogenic or reproductive effects of Salitop™. It has been shown to lack mutagenic potential in the Ames Salmonella test.

Drug Interactions

The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of Salitop™ is not known.

I.
Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:
DRUG DESCRIPTION OF INTERACTION
Sulfonylureas Hypoglycemia potentiated.
Methotrexate Decreases tubular reabsorption; clinical toxicity from methotrexate can result.
Oral Anticoagulants Increased bleeding.
II.
Drugs changing salicylate levels by altering renal tubular reabsorption.
DRUG DESCRIPTION OF INTERACTION
Corticosteroids Decreases plasma salicylate level; tapering doses of steroids may promote salicylism.
Acidifying Agents Increases plasma salicylate level.
Alkanizing Agents Decreased plasma salicylate levels.
III.
Drugs with complicated interactions with salicylates:
DRUG DESCRIPTION OF INTERACTION
Heparin Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients.
Pyrazinamide Inhibits pyrazinamide-induced hyperuricemia.
Uricosuric Agents Effect of probenemide, sulfinpyrazone and phenylbutazone inhibited.

The following alterations of laboratory tests have been reported during salicylate therapy:

LABORATORY TESTS EFFECT OF SALICYLATES
Thyroid Function Decreased PBI; increased T3 uptake.
Urinary sugar False negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5 g q.d.).
5-Hydroxyindole-acetic acid False negative with fluorometric test.
Acetone, ketone bodies False positive FeCl3 in Gerhardt reaction; red color persists with boiling.
17-OH corticosteroids False reduced values with >4.8 g q.d. salicylate.
Vanilmandelic acid False reduced values.
Uric acid May increase or decrease depending on dose.
Prothrombin Decreased levels; slightly increased prothrombin time.

Adverse Reactions

Excessive erythema and scaling conceivably could result from use on open skin lesions.

Overdosage

See WARNINGS.

Salitop Lotion Dosage and Administration

The preferable method of use is to apply Salitop™ thoroughly to the affected area and cover the area at night, after washing and before retiring. Preferably, the skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed, a bland cream or lotion may be applied. Once clearing is apparent, the occasional use of Salitop™ will usually maintain the remission. In those areas where occlusion is difficult or impossible, application may be made more frequently; hydration by wet packs or baths prior to application apparently enhances the effect. (see WARNINGS). Unless hands are being treated, hands should be rinsed thoroughly after application. Excessive repeated application of Salitop™ will not necessarily increase it's therapeutic benefit, but could result in increased local intolerance and systemic adverse effects such as salicylism.

How is Salitop Lotion Supplied

Salitop™Cream is available in 400 gram oval-shaped container, (NDC 51991-476-46).

Salitop™Lotion is available in 14 fl. oz. (414 mL) bottles, (NDC 51991-477-47).

Store at 25° C (77° F); excursions permitted to 15° – 30° C (59° – 86° F). See USP Controlled Room Temperature. Protect from freezing.

Dispense in original containers.

WARNING: Keep this and all medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a poison control center immediately.

All prescription substitutions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.

IN-47646
Rev. 2/09

Distributed by:
Breckenridge Pharmaceutical, Inc.
Boca Raton, FL 33487

Manufactured by:
Groupe Parima, Inc.
Montreal, Qc H4S 1X6 Canada

PRINCIPAL DISPLAY PANEL - 414 mL Bottle Label

Breckenridge
Pharmaceutical, Inc.

NDC 51991-477-47

SALITOP
LOTION
(6% Salicylic Acid)

WARNING:
FOR DERMATOLOGICAL USE ONLY
NOT FOR:

  • OPHTHALMIC USE
  • ORAL USE
  • INTRAVAGINAL USE

Rx Only

Net Contents 14 fl. oz (414 mL)

SALITOP 
salicylic acid lotion
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51991-477
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Salicylic Acid (Salicylic Acid) Salicylic Acid 0.06 g  in 1 mL
Inactive Ingredients
Ingredient Name Strength
Ammonium Lactate  
Behentrimonium Chloride  
Cetyl Alcohol  
Dimethicone  
Edetate Disodium  
Glycerin  
Glyceryl Monostearate  
Methylparaben  
Mineral Oil  
PEG-100 Stearate  
Propylparaben  
Water  
Trolamine  
Product Characteristics
Color WHITE Score     
Shape Size
Flavor Imprint Code
Contains         
Packaging
# Item Code Package Description
1 NDC:51991-477-47 414 mL in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 03/01/2007 09/30/2011
Labeler - Breckenridge Pharmaceutical, Inc. (150554335)
Establishment
Name Address ID/FEI Operations
Groupe Parima 252437850 MANUFACTURE
Revised: 01/2011
 
Breckenridge Pharmaceutical, Inc.
Hide
(web3)